News And Events
Natera
22 March 2022
Natera developed a personalized, tumor-informed approach for molecular residual disease (MRD) detection by using Signatera after surgery to evaluate the need for adjuvant chemotherapy and potentially avoid unnecessary treatment. For more information, you refer to https://natera.showpad.com/share/tjYrvLiWX9XKSTyjfJJL3